CJC-1295

Also known as: CJC-1295 DAC, Modified GRF 1-29

GH/GHRH Research Compound

Growth hormone-releasing hormone analog

Mechanism of Action

Stimulates growth hormone release from the pituitary. Often combined with a GHRP for synergistic effects.

66.7% of observational mentions of CJC-1295 (n=78) reference concurrent use with Ipamorelin, making it one of the most stack-dependent peptides in available data. A GHRH analog (also known as CJC-1295 DAC or Modified GRF 1-29), it has no FDA approval for human use. Self-reported outcomes most frequently center on body composition (36.4%), sleep quality (21.8%), and growth hormone effects (20.0%).

78
Community Posts
55
Users Discussing
2
Research Articles
0

Reported Outcomes

Clinical grade reflects published research; Community grade reflects user reports (n=78).

Body Composition

Changes in muscle vs fat ratio

Clinical: D
Community: B
36% (23)
Sleep Quality

Effects on sleep quality

Clinical: D
Community: B
22% (15)
Growth Hormone

Effects on growth hormone levels

Clinical: C
Community: A
20% (14)

The provided abstracts classify CJC-1295 as a growth hormone-releasing hormone (GHRH) targeted in anti-doping protocols. The texts focus on analytical detection methods (LC-HRMS/MS) and pharmacokinetics (detection windows) in plasma rather than measuring physiological changes in growth hormone levels.

Energy Levels

Changes in energy and fatigue levels

Clinical: D
Community: B
15% (10)
Mental/Mood

Effects on mood and cognitive function

Clinical: D
Community: A
11% (8)

Who Discusses CJC-1295

From community reports with demographic data.

Gender

Male 85%
Female 15%

n=33

Age Distribution

49.5
median age
range: 26-59
<30
30s
40s
50s

n=12

Side Effects

Limited data

Based on 3 user reports (n=3). Frequency indicates how often each was mentioned.

Uncommon (1-5%)

Post Injection Pain (Pip)
Mild 1 reports 12.5%
Bump And Redness At Injection Site
Mild 1 reports 12.5%
Injection Site Pain
Mild 1 reports 12.5%
Skin Ripping
Mild 1 reports 12.5%
Gi Distress
Mild 1 reports 12.5%
Nausea
Mild 1 reports 12.5%
Digestive Upset
Mild 1 reports 12.5%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

i

Water Retention

4 mentions

Fluid retention can occur with GH-releasing peptides. Usually mild and temporary.

Dosing

Standard Protocol

Starting Dose
100mcg 1-3x daily (no DAC) or 2mg weekly (with DAC)
Titration
No established protocol
Half-life
~30 min (no DAC) or ~8 days (with DAC)
Administration
Subcutaneous injection

Community Dosing Patterns

Based on 47 mentions

Community-reported patterns, not medical advice.

200mcg daily
2
daily
2
0.2mg daily
1
5x/week
1
100ug 5 days on, 2 days off
1

Pricing

Research-grade reference pricing for 5mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.

We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.

US Research Grade

$35.5

Single small vial from US domestic vendors

US Research (Bulk)

$28.03

Per-dose equivalent when buying larger US vials

China Research

$9.25

Per-vial when buying 10-pack from Chinese vendors

Research

2
Total Articles
0 0

Key Studies

Probing for peptidic drugs (2-10 kDa) in doping control blood samples Preclinical

Anal Sci Adv (2022)

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS Preclinical

Anal Bioanal Chem (2016)

Commonly Stacked With

Based on 78 community posts mentioning CJC-1295.

Ipamorelin 52 mentions (66.7%)
Tesamorelin 27 mentions (34.6%)
Retatrutide 11 mentions (14.1%)
TB-500 11 mentions (14.1%)
MOTS-c 11 mentions (14.1%)

Switching Patterns

Based on 6 discussions about switching to or from CJC-1295.